Clinical trial · no report yet · Phase 3
SunRISe-2
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
- NCT04658862 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 33 | |
| YouTube | 20 | |
| Podcasts | 20 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Cetrelimab; TAR-200; Cisplatin; Gemcitabine; Conventional radiation therapy; Hypo-fractioned radiation therapy
- Arms
- TAR-200 + Cetrelimab · Experimental
- Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy · Active comparator
- Enrollment
- 518
- Primary outcomes
- Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event
- Sponsor
- Janssen Research & Development, LLC
- Start
- Dec 7, 2020
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04658862 · updated Sep 25, 2026